ClinicalTrials.gg
WithdrawnNCT01643252Updated Apr 26, 2021

Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

A Phase 3 interventional study of riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system and placebo: 0.0% riboflavin ophthalmic solution with the KXL system in Corneal Ectasia, sponsored by Glaukos Corporation. Withdrawn. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment

Why this study was withdrawn
This study was withdrawn for business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

Read the detailed description

The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

02

Conditions studied

  • Corneal Ectasia

Keywords

  • Corneal Ectasia
  • Refractive surgery
  • Cross-Linking
03

In context

Dilatation, Pathologic

121 studies on the registry are indexed under Dilatation, Pathologic; 19 are open to participants now.

Browse Dilatation, Pathologic studies →

Lead sponsor

Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following criteria in order to be enrolled into the trial:

  1. Be at least 12 years of age, male or female, of any race;
  2. Provide written and sign a HIPAA form. Patients who are under the age of 18 will need to sign an assent form as well as having a parent or legal guardian sign an informed consent;
  3. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
  4. For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of the study eye and prior to treatment of a fellow and/or cross-over eye; must not be lactating, and must agree to use a medically acceptable form of for at least one week prior to the randomization visit, one week prior to treatment of a fellow eye or cross-over eye, and continue to use the method for one month following the last treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  5. Having a diagnosis of corneal ectasia after refractive surgery;
  6. Having axial topography consistent with corneal ectasia;
  7. Presence of central or inferior steepening on the Pentacam map;
  8. BSCVA (Best Spectacle Corrected Visual Acuity) of ≥ 1 letter and ≤ 80 letters on ETDRS (Early Treatment of Diabetic Retinopathy Study) chart;
  9. Contact Lens Wearers Only: Removal of contact lenses is required for a 1 week period prior to the screening visit(s);
  10. Contact Lens Wearers Only: Manifest refraction must be stable between two visits which occur at least 7 days apart. A stable refraction is one in which the manifest refraction spherical equivalent and the average K (Km) on the Pentacam taken at the first visit do not differ by more than 0.75 D from the respective measurements taken at the second exam.

Exclusion criteria

Exclusion Criteria

Patients must not meet any of the following criteria in order to be enrolled into the trial:

  1. , sensitivity or known allergy to the use of the test article(s) or their components;
  2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
  3. A history of previous corneal surgery or the insertion of Intacs in the eye(s) to be treated.
  4. A history of previous Limbal Relaxing Incision (LRI) procedure in the eye(s) to be treated;
  5. Corneal pachymetry that is \< 375 microns prior to epithelial debridement at the thinnest point measured by Pentacam in the eye to be treated;
  6. Eyes which are aphakic;
  7. Eyes which are pseudophakic and do not have a UV blocking lens implanted;
  8. Eyes that have the maximum corneal curvature (Kmax) outside of the central 5mm zone as measured by the Pentacam;
  9. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:

    1. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, corneal melt, corneal dystrophy, etc.);
    2. corneal scarring in the cross-linking treatment zone that is not related to corneal ectasia or, in the investigator's opinion, will interfere with the cross-linking procedure;
  10. A history of delayed epithelial healing in the eye to be treated;
  11. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
  12. Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing;
  13. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.
  14. A history of previous corneal crosslinking treatment in the eye to be treated;
  15. Have used an drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device trial within 30 days of the study;
  16. In addition, the Investigator may exclude or discontinue any subject for any sound medical reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo and UVA light exposure

    Drug: placebo: 0.0% riboflavin ophthalmic solution with the KXL system

  • Active comparator
    Riboflavin drops and UVA light exposure

    Drug: riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system

Interventions

  • Drugriboflavin: 0.12% riboflavin ophthalmic solution with the KXL system

    Drug page: Riboflavin

    Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes

  • Drugplacebo: 0.0% riboflavin ophthalmic solution with the KXL system

    Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes

06

What researchers measure

Primary outcomes

  1. Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control group

    Time frame: Baseline to 6 months

  2. Safety

    The primary safety endpoints are loss of BSCVA beginning at the 6 month follow-up examination, specifically, the percentage of eyes that have a loss of 15 or more letters in BSCVA on the ETDRS chart as compared to baseline and the incidence of serious ophthalmic adverse events.

    Time frame: 12 months

Secondary outcomes

  1. Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control group

    Time frame: Baseline to 12 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01643252
Responsible party
Sponsor
First posted
Jul 18, 2012
Start date
Jul 2012
Last update
Apr 26, 2021

Study contacts

Vineeta Belanger
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion